Crossmark

Clinical efficacy and safety of a single administration of fluralaner injectable suspension (BRAVECTO® injectable) vs. monthly administration of oral afoxolaner (NexGard®) in dogs for tick and flea control over one year under European field conditions

Crossref DOI link: https://doi.org/10.1186/s13071-024-06590-1

Published Online: 2024-12-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Petersen, Ivo

Goebel-Lauth, Susanne

Pobel, Thierry

Gil, Maria J.

Löhlein, Wolfgang

Wolf, Oliver

Zschiesche, Eva

Welzel, Bjoern

Heinau, Lea
Funding

Funding for this research was provided by:

MSD Animal Health Innovation GmbH
License Information

Text and Data Mining valid from 2024-12-09

Version of Record valid from 2024-12-09
More Information

Article History

Received: 19 July 2024

Accepted: 17 November 2024

First Online: 9 December 2024

Declarations

:

: This study was conducted in compliance with local and national regulations.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below